Loading
companiesCompany
Neutron Therapeutics
Neutron Therapeutics makes a compact particle accelerator that produces the neutron beam needed for boron neutron capture therapy, a form of radiotherapy that targets cancer cells one at a time, so hospitals no longer need a nuclear reactor to offer it.
Overview
Neutron Therapeutics, founded in November 2015 with roots in MIT technology, builds nuBeam, an accelerator-based neutron source for boron neutron capture therapy (BNCT). It pairs a patented electrostatic proton accelerator (nominal 30 mA at 2.6 MeV) with a rotating solid lithium target to produce an epithermal beam designed to meet IAEA recommendations. The first nuBeam suite is at Helsinki University Hospital, where a full treatment workflow was completed in 2022; a second system at Shonan Kamakura General Hospital in Japan produced its first beam in January 2023, and a research accelerator was accepted at the University of Birmingham in December 2023. In 2023 the company partnered with boron drug developer Aviko Radiopharmaceuticals and with Leo Cancer Care. nuBeam is investigational and not FDA or PMDA approved. No financing round could be sourced.
Headquarters
Danvers, MA, US
Stage
Startup
Website
Founded
2015
Notes
top- Danvers, MA taken from company press release datelines; the Dec 2023 release was datelined Boston. Business Wire copies of the Helsinki and Aviko releases returned HTTP 403, so those milestones are cited to the company's own news page listing. No funding or investor information found in primary sources; stage set to startup by default. Whether patients have been treated clinically at Helsinki could not be confirmed.
Similar pages
- CompanyTAE Life Sciences
Shares Boron neutron capture therapy, Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex), Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Glioma & glioblastoma.
- CompanyStella Pharma
Shares Boron neutron capture therapy, Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex), Glioma & glioblastoma, Head and neck squamous cell carcinoma.
- CompanyNeuboron Medtech
Shares Boron neutron capture therapy, Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex).
- CompanySumitomo Heavy Industries
Shares Boron neutron capture therapy, Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex).
- TrialTo Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies
Shares Boron neutron capture therapy, Head and neck squamous cell carcinoma.
- IdeactHPV-DNA-adapted de-escalation of chemoradiation
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Head and neck squamous cell carcinoma.
- TreatmentAmifostine
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Head and neck squamous cell carcinoma.
- TechnologyRadiodynamic therapy and radiosensitising nanoparticles
Shares Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH, Head and neck squamous cell carcinoma.